“In our complaint, we allege that Decision Diagnostics and Berman repeatedly made baseless representations to the investing public about market-moving events like progress in obtaining FDA approval and having breakthrough technology,” said Anita B. Bandy, Associate Director of the Division of Enforcement.
The SEC filed the complaint against the defendants in the U.S. District Court for the Southern District of New York. Decision Diagnostics and Berman were accused of violating antifraud provisions of the securities laws.
—————————————-
Have a story you want USA Herald to cover? Submit a tip here and if we think it’s newsworthy, we’ll follow up on it.
Want to contribute a story? We also accept article submissions – check out our writer’s guidelines here.
